267 related articles for article (PubMed ID: 12641520)
1. Response, relapse and mucosal immune regulation after infliximab treatment in fistulating Crohn's disease.
Agnholt J; Dahlerup JF; Buntzen S; Tøttrup A; Nielsen SL; Lundorf E
Aliment Pharmacol Ther; 2003 Mar; 17(5):703-10. PubMed ID: 12641520
[TBL] [Abstract][Full Text] [Related]
2. Increased production of granulocyte-macrophage colony-stimulating factor in Crohn's disease--a possible target for infliximab treatment.
Agnholt J; Kelsen J; Brandsborg B; Jakobsen NO; Dahlerup JF
Eur J Gastroenterol Hepatol; 2004 Jul; 16(7):649-55. PubMed ID: 15201577
[TBL] [Abstract][Full Text] [Related]
3. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease.
Gao Q; Hogezand RA; Lamers CB; Verspaget HW
Aliment Pharmacol Ther; 2004 Sep; 20(5):585-92. PubMed ID: 15339330
[TBL] [Abstract][Full Text] [Related]
4. Fistulating anal Crohn's disease: results of combined surgical and infliximab treatment.
Hyder SA; Travis SP; Jewell DP; McC Mortensen NJ; George BD
Dis Colon Rectum; 2006 Dec; 49(12):1837-41. PubMed ID: 17041753
[TBL] [Abstract][Full Text] [Related]
5. Early changes in rectal nitric oxide and mucosal inflammatory mediators in Crohn's colitis in response to infliximab treatment.
Ljung T; Axelsson LG; Herulf M; Lundberg JO; Hellström PM
Aliment Pharmacol Ther; 2007 Apr; 25(8):925-32. PubMed ID: 17402996
[TBL] [Abstract][Full Text] [Related]
6. Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease.
Di Sabatino A; Ciccocioppo R; Cinque B; Millimaggi D; Morera R; Ricevuti L; Cifone MG; Corazza GR
Gut; 2004 Jan; 53(1):70-7. PubMed ID: 14684579
[TBL] [Abstract][Full Text] [Related]
7. Mucosal healing of ileal lesions is associated with long-term clinical remission after infliximab maintenance treatment in patients with Crohn's disease.
Beppu T; Ono Y; Matsui T; Hirai F; Yano Y; Takatsu N; Ninomiya K; Tsurumi K; Sato Y; Takahashi H; Ookado Y; Koga A; Kinjo K; Nagahama T; Hisabe T; Takaki Y; Yao K
Dig Endosc; 2015 Jan; 27(1):73-81. PubMed ID: 24833527
[TBL] [Abstract][Full Text] [Related]
8. Clinical use of Infliximab in Crohn's disease: the Edinburgh experience.
Arnott ID; McDonald D; Williams A; Ghosh S
Aliment Pharmacol Ther; 2001 Oct; 15(10):1639-46. PubMed ID: 11564005
[TBL] [Abstract][Full Text] [Related]
9. Response of fistulating Crohn's disease to infliximab treatment assessed by magnetic resonance imaging.
Bell SJ; Halligan S; Windsor AC; Williams AB; Wiesel P; Kamm MA
Aliment Pharmacol Ther; 2003 Feb; 17(3):387-93. PubMed ID: 12562451
[TBL] [Abstract][Full Text] [Related]
10. Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis.
Keating GM; Perry CM
BioDrugs; 2002; 16(2):111-48. PubMed ID: 11985485
[TBL] [Abstract][Full Text] [Related]
11. Predictive value of mucosal TNF-alpha transcripts in steroid-refractory Crohn's disease patients receiving intensive immunosuppressive therapy.
Schmidt C; Giese T; Hermann E; Zeuzem S; Meuer SC; Stallmach A
Inflamm Bowel Dis; 2007 Jan; 13(1):65-70. PubMed ID: 17206641
[TBL] [Abstract][Full Text] [Related]
12. Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn's disease.
Schmitt H; Billmeier U; Dieterich W; Rath T; Sonnewald S; Reid S; Hirschmann S; Hildner K; Waldner MJ; Mudter J; Hartmann A; Grützmann R; Neufert C; Münster T; Neurath MF; Atreya R
Gut; 2019 May; 68(5):814-828. PubMed ID: 29848778
[TBL] [Abstract][Full Text] [Related]
13. Infliximab in treatment of Crohn's disease: the Milan experience.
Ardizzone S; Colombo E; Maconi G; Bollani S; Manzionna G; Petrone MC; Bianchi Porro G
Dig Liver Dis; 2002 Jun; 34(6):411-8. PubMed ID: 12132788
[TBL] [Abstract][Full Text] [Related]
14. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis.
Baert FJ; D'Haens GR; Peeters M; Hiele MI; Schaible TF; Shealy D; Geboes K; Rutgeerts PJ
Gastroenterology; 1999 Jan; 116(1):22-8. PubMed ID: 9869598
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcome of perianal fistulizing Crohn's disease treated with infliximab.
Bouguen G; Siproudhis L; Gizard E; Wallenhorst T; Billioud V; Bretagne JF; Bigard MA; Peyrin-Biroulet L
Clin Gastroenterol Hepatol; 2013 Aug; 11(8):975-81.e1-4. PubMed ID: 23376316
[TBL] [Abstract][Full Text] [Related]
16. Combined approach with infliximab, surgery, and methotrexate in severe fistulizing anoperineal Crohn's disease: results from a prospective study.
Roumeguère P; Bouchard D; Pigot F; Castinel A; Juguet F; Gaye D; Capdepont M; Zerbib F; Laharie D
Inflamm Bowel Dis; 2011 Jan; 17(1):69-76. PubMed ID: 20623697
[TBL] [Abstract][Full Text] [Related]
17. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
[TBL] [Abstract][Full Text] [Related]
18. Infliximab in the surgical management of complex fistulating anal Crohn's disease.
Talbot C; Sagar PM; Johnston MJ; Finan PJ; Burke D
Colorectal Dis; 2005 Mar; 7(2):164-8. PubMed ID: 15720356
[TBL] [Abstract][Full Text] [Related]
19. Anti-tumour necrosis factor therapy enhances mucosal healing through down-regulation of interleukin-21 expression and T helper type 17 cell infiltration in Crohn's disease.
Liu C; Xia X; Wu W; Wu R; Tang M; Chen T; Xu F; Cong Y; Xu X; Liu Z
Clin Exp Immunol; 2013 Jul; 173(1):102-11. PubMed ID: 23607532
[TBL] [Abstract][Full Text] [Related]
20. Mucosal cytokine production during remission after resection for Crohn's disease and its relationship to future relapse.
Yamamoto T; Umegae S; Kitagawa T; Matsumoto K
Aliment Pharmacol Ther; 2004 Mar; 19(6):671-8. PubMed ID: 15023169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
